Curaleaf Holdings, Inc.

What they do

Curaleaf develops, manufactures, and distributes cannabis products — flower, pre-rolls, vaporizer cartridges, edibles, concentrates, topicals, tinctures, and beverages — under national brands such as Select, Grassroots, Find, and JAMS, plus international brands Curaleaf, Four20 Pharma, and Huala. Domestically, it sells through 173 owned and managed retail locations and over 1,300 wholesale partner accounts. Internationally, it distributes through clinics, pharmacies, and telemedicine platforms, supported by 18 cultivation sites with roughly 1.5 million square feet of capacity.

Revenue drivers

• U.S. retail and wholesale cannabis — The largest revenue source, generated through 173 owned and managed dispensaries and over 1,300 wholesale accounts across 14 states; domestic revenue grew 7% year-over-year in Q2 2026.
• International medical cannabis — Generated $51 million in Q2 2026, up 26% year-over-year, sold through clinics, pharmacies, and telemedicine in 15 countries, led by Germany, the U.K., Poland, and Australasia.
• Branded product portfolio — Ten national and international brands across flower, pre-rolls, vaporizer cartridges, and edibles; the company states its portfolio holds a leading U.S. market share position according to Hoodie Analytics.
• Licensing and wholesale partnerships — Asset-light brand-licensing deals and wholesale partnerships complement owned distribution to widen market exposure while managing capital allocation.

Recent performance

Second quarter 2026 net revenue was $340.1 million, up 10% year-over-year from $310.6 million, with domestic revenue up 7% and international up 26%. Gross profit was $169.9 million, a 50% margin, up 70 basis points year-over-year. Net income attributable to Curaleaf from continuing operations was $12.5 million, or $0.05 per share, and adjusted EBITDA was $70.1 million, a 20.6% margin, down 120 basis points year-over-year. For the six months ended June 30, 2026, revenue was $664.3 million, up 8%, with net income of $82.6 million and adjusted EBITDA of $133.5 million.

Strategy

Management describes a 'Built for Growth' strategy focused on customer centricity, brand building, and operational excellence, with the U.S. business having posted two consecutive quarters of year-over-year domestic growth. The company expanded its Florida retail footprint to 73 dispensaries and launched the ultra-premium Dark Heart flower brand across 11 states. It completed the buyout of the remaining 45% equity interest in Four20 Pharma, bringing Curaleaf International to 100% ownership, and applied to register all medical cultivation, processing, and dispensing locations with the DEA. Curaleaf Spain received approval for two cannabis-related licenses post-quarter. The company retired and repurchased 1.01 million shares for $7.4 million in the first half of 2026.

Risks

• Regulatory and DEA registration risk — The company has applied to register all medical cultivation, processing, and dispensing locations with the DEA, and its business depends on U.S. federal and state cannabis regulation that remains uncertain.
• Persistent net losses — Curaleaf reported annual net losses every year from 2021 through 2025, ranging from $205.9 million to $370.1 million, despite positive operating cash flow in recent years.
• Leverage and liquidity — As of June 30, 2026, long-term debt was $570.5 million against $94.6 million in cash and equivalents on the balance sheet, though the earnings release cites $107 million in total cash.
• Competitive and illicit market pressure — The company states the cannabis industry is highly competitive and that it competes with both legal and illicit operators on quality, price, brand recognition, and distribution strength.

Outlook

Management said the second quarter results reinforce that its 'Built for Growth' strategy is gaining traction and that the U.S. business has regained momentum with two consecutive quarters of domestic year-over-year growth. CEO Boris Jordan stated there is still work ahead and significant opportunity to capture, and that the company believes it has the team, strategy, and operating discipline to lead the next phase of cannabis. No specific numerical guidance for future periods was provided in the excerpted materials.